Power interruptions and remediation work at AMRI’s Albuquerque, New Mexico facility, as well as unexpected delays to API shipments have driven down the company’s Q3 profits.
API, drug intermediates and formulations firm Granules India ended the second quarter of fiscal 2013 with higher revenue and profit thanks to gains made by all three of its units.
Canadian CMO Patheon’s second quarter revenues increased almost 40 percent as the company’s commercial manufacturing services revenues saw a similarly high rise over the same period from last year.
Granules India saw API sales rocket in the fiscal first quarter due – according to the firm – to an efficiency drive and the impact of rising prices in China.
Catalent Pharma Solutions says gains made by its oral delivery tech business and clinical segment offset falling demand for packaging and sterile services in the first quarter of fiscal 2012.
Alkermes saw losses increase in fiscal 2011 but has issued an upbeat outlook on higher revenues, portfolio expansion and impending acquisition of Elan Drug Technologies (EDT).
ShangPharma said it saw revenue climb on higher customer spending in the fourth quarter, but that margins slid due to currency effects and higher share-based compensation.
A customer decision to halt development of an antibiotic and end a manufacturing contract early helped Patheon to an improved set results for the first quarter of fiscal 2011.
Outsourcing-Pharma reviews the latest financial reports from the eClinical sector with news from Datatrak International, Medidata Solutions and Perceptive Informatics.
Cost cutting measures helped Parexel to one of its most profitable quarters after taking lower-than-expected revenues on project delays and cancellations.
Bioanalytical Systems, Inc (BASi) posted an operating profit in the third quarter, overturning a loss 12 months ago, as lower expenses offset a slight dip in revenue.
Pacific Biomarkers (PBI) says “chaotic” drug discovery environment will continue for the rest of fiscal 2010 and cuts revenue forecast as expected recovery fails to materialise.
WuXi PharmaTech posted an operating profit of $52m (€38m) in 2009 and is optimistic about 2010, when it will make investments in laboratory services and large-scale manufacturing to drive growth in coming years.
West Pharmaceutical Services reported strong fourth quarter results, underpinned by demand for H1N1 components, but still posted a dip in operating income for its 2009 financial year.
Full-year income at the Lonza was hit by falling demand for life science ingredients and custom manufacturing services and only modest gains for its bioscience unit.
In Q3 Phase Forward’s revenues from CROs grew by 44 per cent year-on-year and it predicts a bright 2010, as a backlog of delayed trials are started and big pharma attempts to cut IT costs.
Increased focus on international markets, soaring demand for finished dosage forms and improved capacity usage helped India-based CMO Granules posting record revenues.
Dishman is pushing ahead with its international expansion, increasing efforts to win contracts in the US and Japan and nearing completion of a facility Shanghai, China, which is the first it has built outside of India.
Medidata has followed its successful IPO by posting an operating profit in Q2, having made a loss last year, and giving a positive outlook for the rest of the year.
Accounting errors related to the purchase of ClinPhone reduced Parexel’s operating income by $15.9m (€11.2m) in fiscal 2009 and the impact of these charges will continue into the next year.
Wuxi PharmaTech’s China-based laboratory services grew by 23 per cent in Q2, outstripping expectations and resulting in the company revising its guidance for the business segment.
The declining cost of raw materials helped Synthetech post a 220 per cent increase in operating income in the first quarter of its fiscal year, despite its revenues dropping.
AmerisourceBergen’s contract packaging business believes the outlook for the sector is improving after it posted an 11 per cent rise in operating income in Q3.
UK CRO Chiltern International announced positive financial results for the year ending March 2009, possibly suggesting a bounce for a sector that has been hit by project cancellations.
WuXi PharmaTech’s operating income fell by 25 per cent in Q1, in part because of an 81 per cent drop in revenues from manufacturing, but the company reconfirmed its 2009 financial guidance.
IMA chief financial officer Sergio Marzo says that although demand for its machines has been strong so far this year, the number of orders it receives in the second quarter will provide a better reflection of the pharmaceutical industry’s position.
Falling API sales and “an unprecedented negative economic environment” have forced Perrigo to cut its fiscal 2009 profit forecast and sent stock plummeting by 20 per cent.
US drugmaker and contract manufacturer Peregrine narrowed its losses in the second fiscal quarter ending October 31, as a result of cost-cutting measures.
Canadian contract services company MDS Pharma Services reported disappointing results in its fiscal fourth quarter, with revenues dropping 9 per cent to $112m.
Clinical research organisation Encorium has postponed the release of its third quarter results but said it still expects the figures to be in line with its most up-to-date guidance.
Indian contract drugmaker Anu's Laboratories will focus its efforts
on expanding its presence in the country's booming contract
research and manufacturing (CRAMS) market, according to managing
director Hari Babu.
PharmaNet has found itself back in the red again alter a
disappointing first quarter of 2008 and has announced a series of
cost-cutting measures in response.
Switzerland's Siegfried Holding says that a significant jump in
2007 net profit, up 54 per cent to CHF 49.7m ($50m), vindicates its
decision to refocus on the active pharmaceutical ingredients and
generics sector.
There were distinct signs of faltering progress in the
pharmaceutical business of US-based performance materials supplier
Ferro Corporation during the fourth quarter and year ended 31
December 2007.
Fourth quarter operating profit at Italian packaging automation
firm IMA SpA fell some 8.5 per cent to €27m, while its revenue for
the period declined 4.2 per cent to €147m, although pharma sales,
buoyed by acquisitions, kept its...
Icon has improved its financial position significantly during its
third quarter, while its smaller US rival Kendle saw its profit
slip again, weighed down by charges from a 2006 acquisition.
